North America Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
The North America Filgrastim Market would witness market growth of 7.3% CAGR during the forecast period (2021-2027).
Filgrastim is majorly given for neutropenia that is caused by bone marrow transplantation and chemotherapy in patients. It is one of the supportive therapies used in numerous kinds of cancers. In the past few years, cancer prophylaxis has significantly increased in various developed nations and many governments have taken supportive initiatives for creating awareness and educating people about its early treatment. Thus, such aspects are estimated to propel the growth of the filgrastim market over the forecast period.
Approved biosimilars like Neukine, Colstim, Grafeel, and Filcad that are comparatively inexpensive and widely available in emerging nations, thereby augment the growth of the filgrastim market during the forecast period.
The strong healthcare system of various developed nations of this region including the US and Canada is estimated to fuel the growth of the regional filgrastim market over the forecast period. Factors like the increasing prevalence of chronic diseases and the growing geriatric populations are anticipated to augment the growth of the regional filgrastim market in the coming years.
The presence of various key market players in this region along with the increasing investment in R&D activities to develop more effective products would accelerate the growth of the regional market. In addition, supportive reimbursement policies of the governments in this region, are motivating patients to get their treatment and thus, opening the growth avenues for the players operating in the regional market.
The US market dominated the North America Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $266.7 million by 2027. The Canada market is poised to grow at a CAGR of 9.7% during (2021 - 2027). Additionally, The Mexico market is would showcase a CAGR of 8.7% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
Scope of the Study
Market Segments covered in the Report:
By Drug Type
- Biosimilar and
- Biologic
- Chemotherapy induced Neutropenia
- Chronic Neutropenia and
- Other Indications
- Hospital Pharmacies
- Retail Pharmacies and
- Online Pharmacies
- US
- Canada
- Mexico
- Rest of North America
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Filgrastim Market, by Drug Type
- 1.4.2 North America Filgrastim Market, by Indication
- 1.4.3 North America Filgrastim Market, by Distribution Channel
- 1.4.4 North America Filgrastim Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. North America Filgrastim Market by Drug Type
- 3.1 North America Biosimilar Market by Country
- 3.2 North America Biologic Market by Country
- Chapter 4. North America Filgrastim Market by Indication
- 4.1 North America Chemotherapy induced Neutropenia Market by Country
- 4.2 North America Chronic Neutropenia Market by Country
- 4.3 North America Other Indications Market by Country
- Chapter 5. North America Filgrastim Market by Distribution Channel
- 5.1 North America Hospital Pharmacies Market by Country
- 5.2 North America Retail Pharmacies Market by Country
- 5.3 North America Online Pharmacies Market by Country
- Chapter 6. North America Filgrastim Market by Country
- 6.1 US Filgrastim Market
- 6.1.1 US Filgrastim Market by Drug Type
- 6.1.2 US Filgrastim Market by Indication
- 6.1.3 US Filgrastim Market by Distribution Channel
- 6.2 Canada Filgrastim Market
- 6.2.1 Canada Filgrastim Market by Drug Type
- 6.2.2 Canada Filgrastim Market by Indication
- 6.2.3 Canada Filgrastim Market by Distribution Channel
- 6.3 Mexico Filgrastim Market
- 6.3.1 Mexico Filgrastim Market by Drug Type
- 6.3.2 Mexico Filgrastim Market by Indication
- 6.3.3 Mexico Filgrastim Market by Distribution Channel
- 6.4 Rest of North America Filgrastim Market
- 6.4.1 Rest of North America Filgrastim Market by Drug Type
- 6.4.2 Rest of North America Filgrastim Market by Indication
- 6.4.3 Rest of North America Filgrastim Market by Distribution Channel
- Chapter 7. Company Profiles
- 7.1 Abbott Laboratories
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expense
- 7.2 Amgen, Inc.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
- 7.3 Pfizer, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional Analysis
- 7.3.4 Research & Development Expense
- 7.3.5 Recent strategies and developments:
- 7.3.5.1 Approvals and Trials:
- 7.4 Novartis AG
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental and Regional Analysis
- 7.4.4 Research & Development Expense
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Product Launches and Product Expansions:
- 7.5 Dr. Reddy’s Laboratories Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.5.5 Recent strategies and developments:
- 7.5.5.1 Partnerships, Collaborations, and Agreements:
- 7.5.5.2 Product Launches and Product Expansions:
- 7.6 Teva Pharmaceutical Industries Ltd.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expenses
- 7.6.5 Recent strategies and developments:
- 7.6.5.1 Approvals and Trials:
- 7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expense
- 7.7.5 Recent strategies and developments:
- 7.7.5.1 Partnerships, Collaborations, and Agreements:
- 7.8 Cadila Healthcare Ltd. (Zydus Cadila)
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.9 Apotex, Inc.
- 7.9.1 Company Overview
- 7.9.2 Recent strategies and developments:
- 7.9.2.1 Product Launches and Product Expansions:
- 7.1 Toksöz Group
- 7.10.1 Company Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook